CellPro granted partial stay:
This article was originally published in Clinica
CellPro has been granted a partial stay of the injunction covering its Ceprate SC stem cell concentration system, which has been found to infringe patents held by Johns Hopkins University. The product is licensed to Baxter and Becton Dickinson. A US court of appeals ruling has suspended provisions requiring CellPro to phase down non-US sales of disposable products for use with Ceprate by 25% a quarter in the 12 months to July 1998, pending review of the case on appeal. Total product sales were up by 27% to $8.1 million in the nine months. Net loss for the nine months was $16.6 million, down from $16.8 million.